Clinical Trial Update: Ophthalmologic Safety Study of Pramipexole Immediate Release (IR) Versus Ropinirole in Early Parkinson's Disease (PD) Patients [Phase 4]

View source ↗

Summary

Phase 4 trial comparing ophthalmologic safety of pramipexole immediate-release versus ropinirole in early Parkinson disease; results posted in 2011.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• Pramipexole IR (pramipexole)
• Ropinirole (ropinirole)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Parkinson Disease | Phase 4 | Status: COMPLETED | Results posted: 2011-11-04